Gamida Cell to Present Corporate Highlights at Multiple Investor Conferences in June

Rhea-AI Summary

Gamida Cell Ltd. (Nasdaq: GMDA) announced its participation in key investor conferences in June 2021. Management will present a corporate overview at the JMP Securities Life Sciences Conference on June 16, focusing on growth opportunities from omidubicel and GDA-201, both promising therapies for blood cancers. Additionally, they will hold one-on-one meetings at the A.G.P. Summer Healthcare Symposium on June 17. The company aims for a BLA submission for omidubicel in Q4 2021 and an IND submission for GDA-201 in late 2021, enhancing treatment options for patients requiring bone marrow transplants.

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that company management will present its corporate highlights at the following investor conferences in June:

• JMP Securities Life Sciences Conference, June 16-17, 2021. In a fireside chat at 12:30 p.m. ET on June 16, 2021, management will discuss a corporate overview for 2021 with a special focus on multiple growth opportunities driven by advances in the development of omidubicel, a potentially life-saving NAM-enabled cell therapy with positive Phase 3 clinical data, and based on encouraging preliminary clinical results, NAM-enabled natural killer (NK) cell immunotherapies including GDA-201.
• A.G.P. Summer Healthcare Symposium, June 17, 2021. The company will present its 2021 corporate highlights to investors in one-on-one meetings on June 17, 2021.

In the fourth quarter of 2021, Gamida Cell is targeting a BLA submission for omidubicel, the first potential approval of a cell therapy for blood cancer patients in need of an allogeneic bone marrow transplant. In the second half of 2021, the Company is planning an IND submission to support the initiation of a Phase 1/2 clinical study of cryopreserved, off-the-shelf GDA-201 in patients with follicular and diffuse large b-cell lymphomas.

A live webcast of the JMP Securities fireside chat will be available on the “Investors & Media” section of Gamida Cell’s website at www.gamida-cell.com, and will be available for at least 14 days following the event.

About Gamida Cell

Gamida Cell is an advanced cell therapy company committed to cures for patients with blood cancers and serious blood diseases. We harness our NAM-enabled cell platform to create potential therapies with a curative approach for cancer patients in need of better treatment options. For additional information, please visit www.gamida-cell.com or follow Gamida Cell on LinkedIn or Twitter at @GamidaCellTx.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210609005071/en/

FAQ

What events is Gamida Cell (GMDA) participating in during June 2021?

Gamida Cell will take part in the JMP Securities Life Sciences Conference on June 16 and the A.G.P. Summer Healthcare Symposium on June 17, 2021.

What is the focus of Gamida Cell's presentation at the JMP Securities Life Sciences Conference?

The focus will be on growth opportunities for omidubicel and GDA-201, highlighting their advancements in treating blood cancers.

When is Gamida Cell's BLA submission for omidubicel planned?

Gamida Cell is targeting a BLA submission for omidubicel in the fourth quarter of 2021.

What is GDA-201 and its significance for Gamida Cell (GMDA)?

GDA-201 is a cryopreserved, off-the-shelf therapy that Gamida Cell plans to initiate a Phase 1/2 clinical study for in late 2021, aimed at treating certain lymphomas.

Where can I watch the live webcast of the investor presentation?

The live webcast will be available on Gamida Cell's website under the “Investors & Media” section.